Targets › MYBPC3
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Cardiovascular; next expected readout Aug 2027.
Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. (UniProt, Q14896)
Open in Phaseline: the race on MYBPC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Edgewise Therapeutics | EDG-7500 Cardiac myosin inhibitor | MYBPC3 | Phase 2 | Hypertrophic Cardiomyopathy | Dec 2027 |
| Tenaya Therapeutics | TN-201 Recombinant AAV9 delivering MYBPC3 transgene | MYBPC3 | Phase 1 | Hypertrophic Cardiomyopathy | Aug 2027 |
Hypertrophic Cardiomyopathy (2)
small molecule (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.